# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-011492
Filing Date
2026-03-27
Accepted
2026-03-27 06:03:30
Documents
20
Period of Report
2026-05-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20064945x1_def14a.htm iXBRL | DEF 14A | 1235276
4 |  | ny20064945x1_pc01.jpg | GRAPHIC | 615652
5 |  | ny20064945x1_pc02.jpg | GRAPHIC | 574242
6 |  | ny20064945x1_piecharts0x1.jpg | GRAPHIC | 133376
7 |  | ny20064945x1_pvpchart01x1.jpg | GRAPHIC | 188656
8 |  | ny20064945x1_pvpchart02x1.jpg | GRAPHIC | 151998
9 |  | sig_arthursands.jpg | GRAPHIC | 13771
10 |  | sig_arthursandsx1.jpg | GRAPHIC | 16879
| Complete submission text file | 0001140361-26-011492.txt |  | 6507571

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
2 | INLINE XBRL TAXONOMY EXTENSION - SCHEMA | nrix-20260515.xsd | EX-101.SCH | 3233
3 | INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE | nrix-20260515_lab.xml | EX-101.LAB | 2923
23 | EXTRACTED XBRL INSTANCE DOCUMENT | ny20064945x1_def14a_htm.xml | XML | 246148

Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005
Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: DEF 14A | Act: 34 | File No.: 001-39398 | Film No.: 26800734
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)